Early Access — free while we kick the tires
EdgarHawk

ORMP ORAMED PHARMACEUTICALS INC. Insider Trading

Latest: COO & CBO Sold $611K of Shares · Jul 2026
1 filing analyzed · Latest 2026-07-02

Get alerts for ORMP

Add ORMP to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Insider buys
0
Insider sells
1
Unique insiders
1
Direction
Net selling

Historically, stocks have lagged the S&P 500 by a median ~4% over the 90 days after a high insider sell (n ≈ 9,950, 2021-2026). Past results don't predict the future. How we measure this ↗

July 2026
2026-07-02
high
COO & CBO
137,000 shares
$611,431
@ $4.46
Significance 6/10

COO & CBO Joshua Hexter sold 137,000 shares of ORMP at $4.46 on 2026-07-01, reducing non-derivative holdings by 11.3% while retaining 50,000 stock options.

Joshua Hexter, COO & CBO, executed a single sale of 137,000 shares (137.0K shares) at $4.46 on 2026-07-01 totaling $611,431.00, reducing his non-derivative holdings from 1,210,384 shares to 1,073,384 shares. The sale represents an 11.3% reduction in his non-derivative position; however, Hexter retains 50,000 shares through stock options, preserving a meaningful derivative stake in the company. The timing of this sale coincides with strong recent stock performance: the stock has risen 27.8% over 30 days and 34.5% over 90 days, though it remains 11.4% below its 52-week high of $5.19. ORMP's fundamentals show a growth profile—annual revenue growth of 49.2% and a P/E of 1.71—alongside a recent quarterly revenue of $2,000,000 and substantial net income of $38,310,000, indicating operational profitability. The sale should be understood in the context of Hexter's retained position, which includes both remaining common shares and derivative securities.